SANTEN IS PARTNERING WITH SURGEONS TO BRING DEVICE INNOVATION TO GLAUCOMA SURGERY
Hear it from your peers
A device that delivers predictable and sustainable outcomes will enable earlier surgical intervention.1
More Surgeon Perspectives
“Achieving lower pressures early on with safer options for patients will be beneficial in the long run.”
“A device that enables IOP control even after a patient leaves our practice could help us better prevent progression.”
Sustainable Low IOP
“It’s really important to have a surgical approach where we can get the pressure down and it’s sustained over a significant period of time.”
See glaucoma surgeons discuss ideas for how to improve patient outcomes
What is your experience?
Answer a question and see how your response compares with your peers’
Material science innovations could yield new surgical devices that are more degradation-resistant, biocompatible, and able to produce sustained clinical benefits1
- Some MIGS biomaterials provoke a strong foreign-body reaction, accelerating scarring, fibrosis, and other reactions that ultimately result in device failure
Advances in device design to protect delicate eye tissue and ensure secure placement in the eye could provide more beneficial clinical and patient outcomes1
Santen’s efforts in device innovation could initiate a new era of proactive glaucoma surgery1-3
- A micro-invasive device would help ensure as little trauma to the eye as possible, minimizing the potential for adverse events and complications2
- Innovative device design would help maximize outflow while minimizing risk of hypotony1,3
Sustainable Low IOP
- Subconjunctival drainage has been a proven method for decades to achieve IOP in the low teens4
- A device that minimizes post-op complications and intervention rates would help make early surgical treatment a viable option for achieving sustainable IOP control1
Santen is dedicated to advancing proactive glaucoma care with surgical device innovations.
References: 1. Amoozgar B, Wei X, Lee JH, et al. A novel flexible microfluidic meshwork to reduce fibrosis in glaucoma surgery. PLoS One. 2017;12(3):e0172556. 2. Chan JE, Netland PA. EX-PRESS Glaucoma Filtration Device: efficacy, safety, and predictability. Med Devices (Auckl). 2015;8:381-388. 3. Agrawal P, Bradshaw SE. Systematic literature review of clinical and economic outcomes of micro-invasive glaucoma surgery (MIGS) in primary open-angle glaucoma. Ophthalmol Ther. 2018;7(1):49-73. 4. Bloom P, Au L. “Minimally invasive glaucoma surgery (MIGS) is a poor substitute for trabeculectomy”—the great debate. Ophthalmol Ther. 2018;7(2):203-210.